A study leveraging DoD data provides a comprehensive overview of clinical features, treatment choices, and outcomes of patients with immune mediated necrotizing myopathy relative to those of patients with other idiopathy inflammatory myopathies.
An analysis of data obtained from urine samples in the MUSE and TULIP-1 trial sheds new light on the clinical utility of the RAIL score for identifying disease activity and treatment responders in SLE patients with and without lupus nephritis, respectively
An analysis of Medcare claims data offers clinicians an overview or the effectiveness of sarilumab and tocilizumab in second- and third-line polymyalgia rheumatica treatments relative to conventional immunomodulators, such as methotrexate or azathioprine.
An analysis of data from the National Inpatient Sample offers an overview of risk for adverse delivery outcomes associated with Takayasu arteritis among a real-world cohort of US-based patients.
An analysis of more than 250 pregnancies among women with SLE from the Hopkins Lupus Cohort provides insight into risk of adverse pregnancy outcomes based on serum 25-hydroxy vitamin D levels using real-world data.
An analysis of the National Inpatient Sample offers a deep dive into the risk of adverse outcomes associated with presence of polymyositis or dermatomyositis among patients with congestive heart failure.
An analysis of more than 1 million AFib hospitalizations suggests those with large vessel vasculitis had a nearly 2-fold increase in risk of acute myocardial infarction and a more than 9-fold increase in risk of acute kidney injury.
Data from an analysis of kidney biopsies from the AURORA 2 trial presented at CCR East 2023 offer new insight into the long-term histological impact of voclosporin use on renal function in patients with lupus nephritis.